MTOR and prostate carcinoma: Accordingly, the apparent lack of significance of the protein phosphatase activity of PTEN in prostate tumour supprssion supports, and provides insight into, existing efforts to treat prostate cancers with small molecule inhibitors of PI3K, AKT and mTOR.